The brain has a wall.
NeOnc found a way
around it.
The blood-brain barrier blocks most cancer drugs from ever reaching a brain tumor. NeOnc's lead candidate, intranasal NEO100, is designed to travel the nerve pathways straight toward the tumor, around the barrier that stops most drugs.
NEO100 & NEO212
Phase I to II
applications; protection to 20384
FDA Type B meeting planned
When a brain tumor returns, patients run out of options.
Recurrent high-grade brain tumors are among the hardest cancers in medicine. Two obstacles stack on top of each other: the tumors come back aggressively, and most drugs physically can't reach them.
Relapse is expected
Most high-grade glioma patients recur within 6 to 9 months despite maximal surgery, radiation and chemotherapy.
Survival after recurrence
Median survival once the tumor returns is roughly 6 to 9 months, and for recurrent IDH1-mutant high-grade glioma there is no FDA-approved targeted therapy.
The delivery wall
The blood-brain barrier blocks most oncology drugs from ever reaching therapeutic levels inside the central nervous system.
Go around the wall,
not through it.
NeOnc's NEO drug-development platform has produced two lead candidates. The lead program, intranasal NEO100, is designed to travel the olfactory and trigeminal nerve pathways directly toward the brain, bypassing the bloodstream and the barrier that stops most drugs.
Intranasal, brain-targeted
An ultra-pure pharmaceutical grade of perillyl alcohol (a monoterpene from citrus and peppermint oils), self-administered intranasally to deliver therapy along nerve pathways toward the brain.
Brain-optimized chemo
An orally administered conjugate that links perillyl alcohol to temozolomide (the established chemotherapy standard), designed for better brain penetration than temozolomide alone.
Four clinical programs across CNS cancers.
The pipeline spans the lead intranasal candidate NEO100, in recurrent glioma with expansion into meningioma and pediatric brain tumors, and the oral conjugate NEO212. Development stage and timing are subject to regulatory review and can change.
Phase 2a: NEO100 met its primary endpoint.
In the Phase 2a portion of NEO100-01, intranasal NEO100 was studied in 24 patients with recurrent or progressive IDH1-mutant Grade III and IV glioma who had progressed after radiation and temozolomide. Read the results as an encouraging single-arm signal that still needs confirmation in a randomized trial.5
Also reported
Median overall survival was 26.09 months, with overall survival of 86.7% at 6 months, 60.9% at 12 months and 54.1% at 24 months. NEO100 was well tolerated, with no dose-limiting toxicities and predominantly low-grade adverse events.
Next step: the Company intends to request an FDA Type B meeting to align on a potential registrational path.
The case beyond a single trial.
Reasons an investor might follow this story, alongside the risks, which are real and detailed at the bottom of this page.
Patent portfolio
A global portfolio of approximately 179 issued patents and pending applications, licensed from USC, with protection extending to 2038.4
Large, growing CNS market
Operates within the broad CNS therapeutics market, valued at about $127B in 2025 and projected to reach ~$286B by 2035 (Precedence Research, Feb 2026). NeOnc's addressable brain-cancer indications are a subset.7
USC-rooted science
Founded on research led by a USC neurosurgeon, with an advisory board drawn from Duke, NYU, USC and others.
Global expansion
A regional licensing and affiliate structure designed to expand clinical development and trial enrollment across the GCC and MENA region.
Where NeOnc stands now.
Clinical-stage stories move on data. Here is what has been reported and what the Company has said comes next. Timing is a plan, not a promise, and can change.
NEO100-01 Phase 2a positive
Met its primary endpoint: PFS-6 of 48.9% versus a pre-specified 20% benchmark (p=0.0047), with median overall survival of 26.09 months.5
FDA Type B meeting
The Company intends to request a Type B meeting with the FDA to align on a registrational path for NEO100 in recurrent IDH1-mutant high-grade glioma.
NEO212 (oral)
Completed Phase 1 dose escalation (610 mg recommended Phase 2 dose); the Company has cited FDA feedback pointing to a possible accelerated approval pathway.
Meningioma & pediatric
NEO100 is expanding into meningioma and pediatric brain tumors; it holds FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations.
Read the filings,
not just the pitch.
The best way to evaluate any clinical-stage company is its own primary disclosures. Start with NeOnc's SEC filings and investor materials, and decide for yourself.
Open NeOnc's investor materials →Important disclosures, please read
This page is issued by NeOnc Technologies Holdings, Inc. for general informational purposes only. It is not investment advice or a recommendation, and it is not an offer to sell, or the solicitation of an offer to buy, any security. Nothing here should be relied upon as the basis for an investment decision. Any decision to invest should be made only after reviewing the Company's filings with the U.S. Securities and Exchange Commission.
Forward-looking statements. Statements about the Company's pipeline, clinical plans, expected data timing, potential markets, regulatory strategy and future prospects are forward-looking statements based on current expectations. They involve known and unknown risks and uncertainties, and actual results may differ materially. The Company undertakes no obligation to update forward-looking statements except as required by law.
Clinical and investment risk. NeOnc is a clinical-stage company with no FDA-approved products and no product revenue. Its therapies are investigational. Early-stage and small-sample clinical results may not predict later results, and most drug candidates that enter clinical trials are never approved. The Company expects to need substantial additional capital, which may dilute existing shareholders. NTHI shares may be volatile and illiquid. You could lose your entire investment. Clinical data on this page are drawn from the Company's August 12, 2026 Phase 2a topline press release and its 2026 corporate presentation. The Phase 2a study was single-arm and open-label (n=24); its pre-specified 20% benchmark is a study-design assumption, not a concurrent randomized control, and the results require confirmation in a randomized trial. Preclinical results are laboratory or animal findings that may not translate to humans. See sources below.
Full risk factors are described in NeOnc's SEC filings, available on EDGAR (NeOnc Technologies Holdings, CIK 0001979414) and at investors.neonc.com. Investor relations: Hayden IR. Consult a licensed financial professional before making any investment decision.
Sources & notes
- New primary brain and other CNS tumor cases (US, ~107,100 this year): CBTRUS 2025 Statistical Report (2018-2022 data).
- Survival after recurrence (~6-9 months for current salvage therapy) and no approved targeted therapy for recurrent IDH1-mutant high-grade glioma: NeOnc Technologies Phase 2a press release, August 12, 2026.
- No FDA-approved targeted therapy for the recurrent IDH1-mutant Grade III/IV glioma population: NeOnc Technologies Phase 2a press release, August 12, 2026.
- Patent portfolio (~179 issued and pending; protection to 2038): NeOnc Technologies corporate disclosures, 2026.
- Phase 2a NEO100-01 results (PFS-6 48.9% vs 20% pre-specified benchmark, p=0.0047; median OS 26.09 months; OS 86.7%/60.9%/54.1% at 6/12/24 months; well tolerated; planned FDA Type B meeting): NeOnc Technologies press release, August 12, 2026, and Form 8-K on SEC EDGAR.
- Preclinical and pharmacokinetic figures (3x, 10x, 39x) and published-studies count (63): NeOnc Technologies 2026 corporate presentation; preclinical and laboratory data.
- CNS therapeutics market size: Precedence Research, Central Nervous System Therapeutic Market, February 2026 (~$127B in 2025, projected ~$286B by 2035). This is the broad CNS market, not NeOnc's directly addressable brain-cancer market.